サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：細胞免疫療法の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
市場調査レポート
商品コード
1342894

細胞免疫療法の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測

Global Cellular Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 171 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
細胞免疫療法の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
出版日: 2023年08月01日
発行: Value Market Research
ページ情報: 英文 171 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞免疫療法市場の世界需要は、2022年の93億5,000万米ドルから2030年には673王4,000万米ドルの市場規模に達すると推定され、調査期間2023～2030年のCAGRは24.53%です。

細胞免疫療法は、免疫系の細胞を利用してがんを除去する革新的ながん治療法と定義されています。細胞免疫療法のアプローチには、免疫細胞を直接分離し、その数を単純に増加させるものもあれば、遺伝子治療によって免疫細胞を遺伝子操作し、腫瘍破壊能力を高めるものもあります。細胞免疫療法は、長期にわたってがんを予防し、副作用が少なく、乳がん、前立腺がん、黒色腫、肺がんなど、さまざまながんの治療に成功しているため、旧来の治療法よりも広く好まれています。細胞免疫療法は、免疫細胞をがん特異的な標的に向け、免疫系を活性化して標的に集合させ、骨髄腫細胞を破壊する免疫反応を引き起こすことによって行われます。

市場力学：

細胞免疫療法市場の力強い成長は、従来の治療法よりも免疫療法が受け入れられつつあること、バイオシミラーの台頭、モノクローナル抗体（mAbs）の需要増加、人口増加によるがんの有病率の上昇など、いくつかの要因によってもたらされます。細胞免疫療法の市場は、代替治療の選択肢として免疫療法を選択する患者の生存率の上昇によって拡大すると思われます。細胞免疫療法の市場成長を促進するその他の要因は、医療費の増加、研究開発活動の活発化、医療保険への容易なアクセス、がん治療法の技術的進歩の急増です。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、細胞免疫療法の世界市場における各セグメントを包括的に評価することもできます。細胞免疫療法産業の成長と動向は、本調査に全体的なアプローチを提供します。

地域分析：

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける細胞免疫療法市場の現在と将来の需要を強調した地域展望をカバーします。さらに、すべての主要地域における各用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 細胞免疫療法- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

第6章 細胞免疫療法の世界市場分析：治療タイプ別

  • 治療タイプ別概要
  • 実績データと予測データ
  • 治療タイプ別分析
  • CAR T細胞療法
  • 樹状細胞療法
  • NK細胞療法
  • TIL療法
  • その他

第7章 細胞免疫療法の世界市場分析：適応症別

  • 適応症別概要
  • 実績データと予測データ
  • 適応症別分析
  • B細胞悪性腫瘍
  • 前立腺がん
  • 肝臓がん
  • 腎細胞がん
  • その他

第8章 細胞免疫療法の世界市場売上高分析：最終用途別

  • 最終用途別概要
  • 実績データと予測データ
  • 最終用途別分析
  • 病院
  • がん研究所
  • その他

第9章 細胞免疫療法の世界市場売上分析：地域別

  • 地域別展望販売分析
  • イントロダクション売上分析
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第10章 細胞免疫療法企業の競合情勢

  • 細胞免疫療法市場の競合
  • 提携・共同研究・契約
  • 合併・買収
  • 新製品上市
  • その他の開発

第11章 企業プロファイル

  • 上位10社のシェア分析
  • 市場集中度
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences Inc.（Kite Pharma）
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Pfizer Inc.
  • Johnson & Johnson
  • Celyad
  • Adicet Bio Inc.
  • Dendreon Pharmaceuticals LLC
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Therapy Type (USD MN)
  • CAR T Cell Therapy Market Sales by Geography (USD MN)
  • Dendritic Cell Therapy Market Sales by Geography (USD MN)
  • NK Cell Therapy Market Sales by Geography (USD MN)
  • TIL Therapy Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Indication (USD MN)
  • B-cell Malignancies Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Liver Cancer Market Sales by Geography (USD MN)
  • Renal Cell Carcinoma Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Cancer Institutes Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Cellular Immunotherapy Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cellular Immunotherapy Report
  • Market Research Process
  • Market Research Methodology
  • Global Cellular Immunotherapy Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Therapy Type
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by End-use
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Therapy Type (USD MN)
  • CAR T Cell Therapy Market Sales by Geography (USD MN)
  • Dendritic Cell Therapy Market Sales by Geography (USD MN)
  • NK Cell Therapy Market Sales by Geography (USD MN)
  • TIL Therapy Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • B-cell Malignancies Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Liver Cancer Market Sales by Geography (USD MN)
  • Renal Cell Carcinoma Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Cancer Institutes Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11219156

The global demand for Cellular Immunotherapy Market is presumed to reach the market size of nearly USD 67.34 BN by 2030 from USD 9.35 BN in 2022 with a CAGR of 24.53% under the study period 2023 - 2030.

Cellular immunotherapy is defined as an innovative cancer treatment approach that uses the cells of our immune system to eliminate cancer. Cellular immunotherapy approaches involve directly isolating immune cells & simply multiplying their numbers, whereas others involve genetically engineered immune cells through gene therapy to enhance their tumor-destroying capabilities. Cellular immunotherapy is widely preferred over old treatment because it provides long-term cancer protection, has lesser side effects, and has been successful in treating different cancers such as breast cancer, prostate cancer, melanoma, lung cancer, and many others. Cellular immunotherapy is performed by directing the immune cells toward cancer-specific targets, activating the immune system to assemble at the target, and triggering an immune response capable of destroying myeloma cells.

MARKET DYNAMICS:

This robust growth of the cellular immunotherapy market is driven by several factors such as increasing acceptance of immunotherapy over conventional therapies, growing emergence of biosimilars, increasing demand for monoclonal antibodies (mAbs), and rising prevalence of cancer among a growing population. The market for cellular immunotherapy will increase due to the increased survival rate of patients who choose it as an alternative treatment option. Other factors propelling the market growth of cellular immunotherapy are an increase in healthcare spending, Increasing R&D activities, easy access to medical insurance, and a surge in technological advancements in cancer treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cellular immunotherapy. The growth and trends of cellular immunotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cellular immunotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

  • Car T Cell Therapy
  • Dendritic Cell Therapy
  • NK Cell Therapy
  • TIL Therapy
  • Others

By Indication

  • B-Cell Malignancies
  • Prostate Cancer
  • Liver Cancer
  • Renal Cell Carcinoma
  • Others

By End-Use

  • Hospitals
  • Cancer Institutes
  • Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cellular Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cellular immunotherapy market include Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc. (Kite Pharma), F. Hoffmann-La Roche Ltd, Merck KGaA, GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Johnson & Johnson, Celyad, Adicet Bio Inc., Dendreon Pharmaceuticals LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CELLULAR IMMUNOTHERAPY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Therapy Type
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By End-use
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY THERAPY TYPE

  • 6.1 Overview by Therapy Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Therapy Type
  • 6.4 CAR T Cell Therapy Historic and Forecast Sales by Regions
  • 6.5 Dendritic Cell Therapy Historic and Forecast Sales by Regions
  • 6.6 NK Cell Therapy Historic and Forecast Sales by Regions
  • 6.7 TIL Therapy Historic and Forecast Sales by Regions
  • 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 B-cell Malignancies Historic and Forecast Sales by Regions
  • 7.5 Prostate Cancer Historic and Forecast Sales by Regions
  • 7.6 Liver Cancer Historic and Forecast Sales by Regions
  • 7.7 Renal Cell Carcinoma Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY END-USE

  • 8.1 Overview by End-use
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-use
  • 8.4 Hospitals Historic and Forecast Sales by Regions
  • 8.5 Cancer Institutes Historic and Forecast Sales by Regions
  • 8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CELLULAR IMMUNOTHERAPY COMPANIES

  • 10.1. Cellular Immunotherapy Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CELLULAR IMMUNOTHERAPY INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Bristol-Myers Squibb Company
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Novartis AG
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Gilead Sciences Inc. (Kite Pharma)
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. F. Hoffmann-La Roche Ltd
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Merck KGaA
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. GlaxoSmithKline plc.
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. AstraZeneca
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Pfizer Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Johnson & Johnson
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Celyad
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Adicet Bio Inc.
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Dendreon Pharmaceuticals LLC
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies